drugset / Trial / NCT04540744

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

NCT04540744

Phase 1 Completed 18 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the rate and extent of absorption of macitentan and tadalafil following administration of a single oral dose of a fixed-dose combination (FDC) of 10 milligram (mg)/20 mg macitentan/tadalafil (test), compared to the coadministration as a free combination (reference) of 10 mg macitentan and 20 mg tadalafil under fasted conditions in healthy adult participants.

Timeline

Start
2021-04-30
Primary completion
2021-08-08
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 10 mg Oral
Subject Tadalafil Small molecule 20 mg Oral

Indications

No indication recorded.